March 8: As if it was possible for Novo Nordisks Wegovy to get any hotter, the FDA approved the GLP-1 weight loss drug to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who are obese or overweight
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
These might include persistent constipation, diarrhea, unusual abdominal pain, or symptoms of an allergic reaction like itching, rash, or swelling
Maybe you imagine a leafy, veggie-laden salad or some other healthy, nutrient-rich food